04:33 AM EDT, 06/05/2025 (MT Newswires) -- Hutchmed ( HCM ) and Innovent Biologics said late Wednesday a new drug application for the combination of fruquintinib and sintilimab as a treatment for certain patients with locally advanced or metastatic renal cell carcinoma has been accepted for review by the China National Medical Products Administration.

The application is backed by data from a study evaluating the efficacy and safety of the drug combination, which met its primary endpoint of progression free survival, the companies said.

The combination also showed "improvements" in secondary endpoints including objective response rate and duration of response, the companies said.